EMEA-001407-PIP02-15-M07 - paediatric investigation plan
nivolumab
PIPHuman
Key facts
- Invented name
- Opdivo
- Active Substance
- nivolumab
- Therapeutic area
- Oncology
- Decision number
- P/0138/2024
- PIP number
- EMEA-001407-PIP02-15-M07
- Pharmaceutical form(s)
- Concentrate for solution for infusion
- Condition(s) / indication(s)
- Treatment of malignant neoplasms of lymphoid tissue
- Treatment of malignant neoplasms of the central nervous system
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com
Tel. +44 (0)1423 533610- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date